Por: Associated Press Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. Eisai announced results late Tuesday from a... + full article
ABC News USA Business September 29, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
How To Spot The Early Signs Of Alzheimer's | Newsweek
CNN USA Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary... + más
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say | Portland Press Herald
WPLG Local 10 USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab,... + más
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
The Advocate USA Health September 17, 2022
Are U.S. veterans more at risk for Alzheimer’s or other dementias?The U.S. is in the midst of a dramatic rise in the number of veterans with Alzheimer’s disease and other dementias, and many of these new cases are directly attributable to military service.According to a 2017... + más
Stroke can lead to vascular dementia: Alzheimer's Q&A | The Advocate
Alzheimer's Q&A: Let go of negative thoughts | The Advocate
Is sildenafil being considered as a potential treatment for Alzheimer’s disease?Sildenafil could potentially be used as a treatment for Alzheimer’s disease, according to findings recently published in Nature Aging by Feixong Cheng, of the Cleveland Clinic.Per MedlinePlus, an... + más
US warns monkeypox could mutate to resist antiviral drug | ABC News
About iurex | Privacy Policy | Disclaimer |